Gideon Heap

Healthcare analyst @DRGinsights part of @clarivate. Commercial insights into the CV, metabolic, and renal disorder markets

[GoggleDocs @GoggleDocs]

‼️High Dose semaglutide #wegovy now recommend for the management of #obesity in 🇬🇧‼️

✅@NICEComms

https://t.co/oLhaPTANH0

📍2.4mg semaglutide ⤵️ weight by 12.4% over 68 weeks
📍50.5% of people ⤵️ weight by 15%

Check out our video the effectiveness
👇👇👇

[Daniel J Drucker @DanielJDrucker]

@LillyPad highlights strong US Tirzepatide launch #T2D after only 2 quarters

[cardio-met @cardiomet_CE]

1) Welcome to a new #accredited #tweetorial on the latest advances in the management of #CKD in the setting of patients with and without #T2D--this time with a hot-off-the-presses update from #ASN22 #KIDNEYWEEK2022: eagerly-awaited results of the #EMPA_KIDNEY trial.

[Gideon Heap @GideonHealth]

Daprodustst got mixed results from its advisory committee meeting. Panel voted no for non-dialysis, yes for dialysis in renal anemia.
The need for an oral drug such as this is stronger in the non-dialysis population. $GSK

[Gideon Heap @GideonHealth]

@sciencescanner Cardiff?

[Peter Rossing @P_Rossing]

See the new Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and KDIGO https://t.co/QXTdrLiAf8 @Stenodiabetes @goKDIGO @gbakris @deboerih @ADA_DiabetesPro

[Gideon Heap @GideonHealth]

@gerard_meagher Any intel from the cricket desk ?

[Gideon Heap @GideonHealth]

Shout out to the wise 4%

[YouGov @YouGov]

How many holes are there in a straw?

One: 54%
Two: 42%

https://t.co/GxScaapn9H

[Stephanie deGiorgio @DrSdeG]

The very brilliant @DrStuartFlint speaking now at #BOMSS22. Have learned so much about obesity stigma from him and always learn something new when he talks.

[Alfonso Valle @ValleAlfonso]

▶️▶️Preventing and delaying cardiorenal disease
⚠️ #DELIVER, with #HFpEF & #HFmrEF (n=6,263), has met its primary endpoint (CV death + worsening HF)

📍 https://t.co/6lzv6QqtLK @secardiologia @IcyfaSemi

[Claire Davies @claireyrivs]

Don’t let your typo cause a hypo, take care with look-a-like 👀 sound-a-like 👂 insulins 💉
Make sure you know your Humalog from your Humalog Mix25, your Humulin I from your Humulin M3
If I’m doubt double check and ask a member of the pharmacy team 👍
#InsulinSafetyWeek2022

[GoggleDocs @GoggleDocs]

SGLT2i in ACUTE Heart Failure? Watch our quick review of the EMPULSE trial 👉 https://t.co/tj5Nka9YP8 👈 @drkevinfernando @AmarPut @drpatrickholmes @dr_amritlamba

[Muthu Vaduganathan @mvaduganathan]

P3 #EMPAKIDNEY RCT stopped early due to efficacy in #CKD. Congrats @willkidney @Oxford_NDPH & investigators!

Broad clinical profiles
⭐️1/2 w/o diabetes
⭐️1/2 w/ UACR<300mg/g
⭐️1/4 w/ GN

CKD trials likely to have clearest mortality signal across #CaReMe.

https://t.co/Atj9Yx9VN0

[cardio-met @cardiomet_CE]

1) Welcome to a new #accredited #tweetorial from our good friends and #diabetes experts @GoggleDocs, specifically @drkevinfernando, @drpatrickholmes, & @AmarPut. They have put their 🗣️s together to provide us with a summary of the first-ever consensus statement from ...

[Int Society of Nephrology @ISNkidneycare]

In honor of #WorldKidneyDay today, the ISN has dressed the famous #MannekenPis with the colors of @WorldKidneyDay. Special thanks to the city of Brussels for helping us to raise awareness of the high burden of kidney disease worldwide.

[Gideon Heap @GideonHealth]

Madrigal's resmetirom.
MAESTRO-NAFLD-1 placebo arm liver fat change of +8 or -8%?🧐 Makes a massive difference to active arm efficacy.
Its being reported differently within Madrigal and the specialist media.
I'm assuming its -8%. Did $MDGL post a correction? #NASH

[@CKD_ce @ckd_ce]

1) Welcome to a new #accredited #tweetorial on currently available treatments for mineralocorticoid receptor (MR) antagonism (#MRA), the differences among them, and how these differences impact on treatment of cardio-reno-metabolic diseases #CaReMe #FOAMed

[Javier Torres @JTLLERGO]

⚠️ A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction‼️

Via @JACCJournals

@secardiologia @SACardiologia @clinica_sec @ValleAlfonso @SantasEnrique @yulnunezvill

https://t.co/YcXnsGntLl

[Gideon Heap @GideonHealth]

@MedCrisis I cana' believe you did that!

[Gideon Heap @GideonHealth]

EMPULSE trial. The fact that enrollment was irrespective of diabetes is another step toward SGLT-2 inhibitors being recognized as cardiovascular treatments in addition to the type 2 diabetes therapies they were originally developed as. #aha21 #heartfailure https://t.co/uYn0GTB9Vh